Gilead submits NDA for new HIV treatment to FDA

8 April 2015

USA-based Gilead Sciences (Nasdaq: GILD), the world’s leading independent biotech firm, has submitted a New Drug Application to the US Food and Drug Administration for a new HIV treatment.

Gilead has submitted the NDA for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide for the treatment of HIV-1 infection in adults and pediatric patients aged 12 years and older, in combination with other HIV antiretrovirals.

Tenofovir alafenamide is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread (tenofovir disoproxil fumarate), and improved renal and bone laboratory parameters as compared to Viread in clinical trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK